On one hand, calreticulin expression—in the context of chemotherapeutic treatment—in acute myeloid leukemia (n=20), colorectal cancer (n=68), neuroblastoma (n=68), and ovarian cancer (n=22) is favorable. The gene discussed is CALR; the disease is neuroblastoma.